CD38 and lymphoma: In the event of recurrence of the disease, lymphoma specimens will be tested for molecular biology-related indicators, and new treatments such as chemotherapy combined with monoclonal antibodies to programmed cell death protein 1 or programmed cell death ligand 1; histone deacetylase inhibitors; monoclonal antibody to CD38; or immunomodulator lenalidomide will be administered according to the molecular tests and literature findings17.